Tsann Ming Chu is a notable inventor based in Williamsville, NY (US). He has made significant contributions to the field of medical research, particularly in the development of monoclonal antibodies for cancer treatment. With a total of 6 patents, his work has the potential to impact the lives of many patients suffering from breast carcinoma.

Latest Patents

Among his latest patents are methods for the use of a ductal carcinoma antigen. These patents detail the production of monoclonal antibodies that target adenocarcinoma cells, specifically those associated with breast carcinoma. The antibodies are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. These monoclonal antibodies have shown the capability to shrink solid tumors associated with human breast cancer. They identify an antigen associated with carcinomas of ductal lineage, and specifically, the F36/22 monoclonal antibodies can be utilized both diagnostically and therapeutically.

Career Highlights

Throughout his career, Tsann Ming Chu has worked with various organizations, including Health Research, Inc. and Research, Incorporated. His innovative approaches and research have contributed to advancements in cancer treatment and diagnostics.

Collaborations

Some of his notable coworkers include Lawrence D Papsidero and Ming C Wang. Their collaborative efforts have furthered the research and development of effective cancer therapies.

Conclusion

Tsann Ming Chu's contributions to the field of medical research, particularly in the area of cancer treatment, highlight the importance of innovation in healthcare. His work continues to pave the way for new therapeutic options for patients battling breast carcinoma.